Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00352521
Other study ID # Pro00012387
Secondary ID DUMC-8053-05-12R
Status Completed
Phase Phase 2
First received July 13, 2006
Last updated July 18, 2014
Start date April 2006
Est. completion date July 2009

Study information

Verified date February 2013
Source Duke University
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also block blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with irinotecan may kill more tumor cells. Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This phase II trial is studying how well giving bevacizumab together with irinotecan works in treating patients with recurrent malignant glioma and how well MRI predicts response to treatment.


Description:

OBJECTIVES:

Primary

- Examine the effect of bevacizumab and irinotecan on vascular permeability and blood flow in patients with recurrent malignant gliomas.

Secondary

- Determine the reproducibility of dynamic contrast-enhanced (DCE-MRI) in malignant gliomas.

- Determine the predictive value of DCE-MRI in patients with recurrent malignant gliomas treated with bevacizumab and irinotecan.

- Describe the activity of the combination of bevacizumab with irinotecan as measured by response rate and progression-free survival.

- Describe the toxicity associated with the administration of bevacizumab with irinotecan.

OUTLINE: Patients receive bevacizumab IV on days 1, 15, and 29 and irinotecan IV on days 2, 15, and 29 during the first 6-week cycle. After the first cycle, the irinotecan and bevacizumab will be given on days 1, 15 and 29. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

Patients also undergo dynamic contrast-enhanced MRI 4 times.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date July 2009
Est. primary completion date December 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Diagnosis of any of the following malignant gliomas:

- Glioblastoma multiforme

- Anaplastic astrocytoma

- Grade 3 or greater WHO astrocytic, oligodendroglial, or mixed glial tumors that were initially diagnosed by histologic examination of a tumor specimen obtained from biopsy or resection

- Recurrent disease

- No more than 3 prior recurrences

- Measurable recurrent or residual primary CNS neoplasm on contrast-enhanced MRI or CT scan

- No evidence of CNS hemorrhage on baseline MRI or CT scan

PATIENT CHARACTERISTICS:

- Karnofsky performance status 60-100%

- Hematocrit > 29%

- Absolute neutrophil count > 1,500/mm³

- Platelet count > 125,000/mm³

- Creatinine < 1.5 mg/dL

- SGOT < 1.5 times upper limit of normal (ULN)

- Bilirubin < 1.5 times ULN

- Not pregnant or nursing

- Fertile patients must use effective contraception

- No active infection

- No significant traumatic injury within the past 28 days

PRIOR CONCURRENT THERAPY:

- At least 6 weeks since prior surgical resection

- More than 28 days since prior major surgical procedure or open biopsy

- More than 7 days since prior minor surgical procedure, fine-needle aspirations, or core biopsies

- At least 6 weeks since prior chemotherapy*

- At least 4 weeks since prior radiotherapy*

- No concurrent immunosuppressive agents

- No concurrent therapeutic anticoagulation

- Concurrent corticosteroids allowed if dose has been stable for 1 week prior to study entry NOTE: * Unless there is unequivocal evidence of progressive disease

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
bevacizumab

irinotecan

Procedure:
dynamic contrast-enhanced magnetic resonance imaging


Locations

Country Name City State
United States Duke Comprehensive Cancer Center Durham North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Duke University National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation of the acute permeability and blood flow response (24-48 hours) with progression-free survival (PFS) Assessed by DCE-MRI 1 year No
Secondary Overall Survival and Tumor Response 2 years No
Secondary Incidence and severity of central nervous system (CNS) hemorrhage and systemic hemorrhage 2 years Yes
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT00006080 - Fenretinide in Treating Patients With Recurrent Malignant Glioma Phase 2
Recruiting NCT00887146 - Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Phase 3
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Completed NCT00621686 - Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme Phase 2
Terminated NCT00227032 - Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme Phase 1
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Terminated NCT00243022 - Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme Phase 2
Active, not recruiting NCT00087815 - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain N/A
Active, not recruiting NCT00278278 - Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Phase 3
Completed NCT00416819 - Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma N/A
Completed NCT00052286 - Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer N/A
Completed NCT00006093 - EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Phase 1/Phase 2
Recruiting NCT00004129 - Phosphorus 32 in Treating Patients With Glioblastoma Multiforme Phase 1
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00003417 - Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00008008 - Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Phase 2
Completed NCT00003484 - Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors Phase 1
Completed NCT00003464 - Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme Phase 2
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2